|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schmittel A, Sebastian M, von Fischer
Weikersthal L, Martus P, Gauler TC, Kaufmann C, Hortig P, Fischer
JR, Link H, Binder D, et al: A German multicenter, randomized phase
III trial comparing irinotecan-carboplatin with
etoposide-carboplatin as first-line therapy for extensive-disease
small-cell lung cancer. Ann Oncol. 22:1798–1804. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jotte R, Conkling P, Reynolds C, Galsky
MD, Klein L, Fitzgibbons JF, McNally R, Renschler MF and Oliver JW:
Randomized phase II trial of single-agent amrubicin or topotecan as
second-line treatment in patients with small-cell lung cancer
sensitive to first-line platinum-based chemotherapy. J Clin Onco.
29:287–293. 2011. View Article : Google Scholar
|
|
4
|
Gerber DE and Schiller JH: Maintenance
chemotherapy for advanced non-small-cell lung cancer: New life for
an old idea. J Clin Oncol. 31:1009–1020. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rossi A, Garassino MC, Cinquini M,
Sburlati P, Di Maio M, Farina G, Gridelli C and Torri V:
Maintenance or consolidation therapy in small-cell lung cancer: A
systematic review and meta-analysis. Lung Cancer. 70:119–128. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mesiano G, Todorovic M, Gammaitoni L,
Leuci V, Diego Giraudo L, Carnevale-Schianca F, Fagioli F,
Piacibello W, Aglietta M and Sangiolo D: Cytokine-induced killer
(CIK) cells as feasible and effective adoptive immunotherapy for
the treatment of solid tumors. Expert Opin Biol Ther. 12:673–684.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moretta A, Bottino C, Vitale M, Pende D,
Cantoni C, Mingari MC, Biassoni R and Moretta L: Activating
receptors and coreceptors involved in human natural killer
cell-mediated cytolysis. Annu Rev Immunol. 19:197–223. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Carbone E, Neri P, Mesuraca M, Fulciniti
MT, Otsuki T, Pende D, Groh V, Spies T, Pollio G, Cosman D, et al:
HLA class I, NKG2D, and natural cytotoxicity receptors regulate
multiple myeloma cell recognition by natural killer cells. Blood.
105:251–258. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Coudert JD and Held W: The role of the
NKG2D receptor for tumor immunity. Semin Cancer Biol. 16:333–343.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mistry AR and O'Callaghan CA: Regulation
of ligands for the activating receptor NKG2D. Immunology.
121:439–447. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fuertes MB, Girart MV, Molinero LL,
Domaica CI, Rossi LE, Barrio MM, Mordoh J, Rabinovich GA and
Zwirner NW: Intracellular retention of the NKG2D ligand MHC class I
chain-related gene A in human melanomas confers immune privilege
and prevents NK cell-mediated cytotoxicity. J Immunol.
180:4606–4614. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kloss M, Decker P, Baltz KM, Baessler T,
Jung G, Rammensee HG, Steinle A, Krusch M and Salih HR: Interaction
of monocytes with NK cells upon Toll-like receptor-induced
expression of the NKG2D ligand MICA. J Immunol. 181:6711–6719.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lu X, Ohata K, Kondo Y, Espinoza JL, Qi Z
and Nakao S: Hydroxyurea upregulates NKG2D ligand expression in
myeloid leukemia cells synergistically with valproic acid and
potentially enhances susceptibility of leukemic cells to natural
killer cell-mediated cytolysis. Cancer Sci. 101:609–615. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kato N, Tanaka J, Sugita J, Toubai T,
Miura Y, Ibata M, Syono Y, Ota S, Kondo T, Asaka M and Imamura M:
Regulation of the expression of MHC class I-related chain A, B
(MICA, MICB) via chromatin remodeling and its impact on the
susceptibility of leukemic cells to the cytotoxicity of
NKG2D-expressing cells. Leukemia. 21:2103–2108. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bae DS, Hwang YK and Lee JK: Importance of
NKG2D-NKG2D ligands interaction for cytolytic activity of natural
killer cell. Cell Immunol. 276:122–127. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pende D, Rivera P, Marcenaro S, Chang CC,
Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L and
Moretta A: Major histocompatibility complex class I-related chain A
and UL16-binding protein expression on tumor cell lines of
different histotypes: Analysis of tumor susceptibility to
NKG2D-dependent natural killer cell cytotoxicity. Cancer Res.
62:6178–6186. 2002.PubMed/NCBI
|
|
17
|
Friese MA, Platten M, Lutz SZ, Naumann U,
Aulwurm S, Bischof F, Bühring HJ, Dichgans J, Rammensee HG, Steinle
A and Weller M: MICA/NKG2D-mediated immunogene therapy of
experimental gliomas. Cancer Res. 63:8996–9006. 2003.PubMed/NCBI
|
|
18
|
Salih HR, Antropius H, Gieseke F, Lutz SZ,
Kanz L, Rammensee HG and Steinle A: Functional expression and
release of ligands for the activating immunoreceptor NKG2D in
leukemia. Blood. 102:1389–1396. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Linn YC, Lau SK, Liu BH, Ng LH, Yong HX
and Hui KM: Characterization of the recognition and functional
heterogeneity exhibited by cytokine-induced killer cell subsets
against acute myeloid leukaemia target cell. Immunology.
126:423–435. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Morisaki T, Onishi H and Katano M: Cancer
immunotherapy using NKG2D and DNAM-1 systems. Anticancer Res.
32:2241–2247. 2012.PubMed/NCBI
|
|
22
|
Zafirova B, Wensveen FM, Gulin M and Polić
B: Regulation of immune cell function and differentiation by the
NKG2D receptor. Cell Mol Life Sci. 68:3519–3529. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Champsaur M and Lanier LL: Effect of NKG2D
ligand expression on host immune responses. Immunol Rev.
235:267–285. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Spear P, Wu MR, Sentman ML and Sentman CL:
NKG2D ligands as therapeutic targets. Cancer Immun.
13:82013.PubMed/NCBI
|
